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simeters (Landauer, USA) was fabricated. The interven-
tionalist wore the headband for all cases involving fluoros-
copy for one random month. Procedure-related data was
recorded including fluoroscopy time, presence or absence
of fixed shielding, and case type. Data from the bifrontal,
bitemporal and occipital dosimeters was then analyzed.
Results: Forty-three cases involving fluoroscopy were
performed on eighteen days during this month. Total
fluoroscopy time was 239 minutes, or 5.5 minutes per case.
Fluoroscopy times ranged from less than one minute for a
fistulogram with angioplasty to 19.5 minutes for recanaliz-
ing a left subclavian artery chronic total occlusion. Table or
boom-mounted shielding was available for only 42% of
cases. Cases without shielding often involved longer fluo-
roscopy times or smaller distances between the radiation
source and the interventionalist. Dosimetry readings were
highest on the left side. The right- sided doses were 25%
lower, and the occiput received a dose 63% of the highest
(see Table 1).
Conclusions: During a typical month of work, this
interventionalist received the equivalent of sixty skull x-rays
from scatter. This is despite habitually minimizing fluoros-
copy times and maximizing distance from the source and
the use of available shields. Although left- sided cranial
exposure was highest, even the occiput was significantly
exposed. This representative vascular interventionalist
could benefit from better cranial x-ray protection.
Table 1
Dosimeter Total exposure (mrem)
Left Temporal 190
Left Frontal 180
Right Frontal 140
Occipital 120
Right Temporal 110
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Objectives: Traditionally general anesthesia (GA) was
the preferred modality of anesthesia for BKA and AKAs. The
use of regional nerve blocks has recently gained popularity,
however, without the supporting evidence on any mortality
benefits. Our objective is to evaluate whether regional nerve
blocks yield significant mortality reduction in major lower
extremity amputations.
Methods: Retrospective data of both elective AKA and
BKA procedures at the Maimonides Medical Center from2005 to 2009 were analyzed. Patient received either general
sedation, spinal or ultrasound-guided regional nerve blocks as
per decision of attending anesthesiologist. Regional nerve
blocks for major lower extremity amputations consisted of
femoral, sciatic, saphenous and popliteal nerve blocks. A ret-
rospective inquiry of 30-day mortality was performed with
reference to the Social Security Death Index and hospital
records.
Results: One hundred and fifty-eight patients were in-
cluded in the study (82males and86 femaleswithmean age of
74.5 years /-12.9 SD, range of 33 to 98 years) of which 46
patients had regional nerve blocks and 112 had GA or spinal
blocks. Patients who received both regional blocks and GA/
spinal blocks within 30 days were excluded. The overall 30-
day mortality was 17.1% (27 patients) consisted of 15.2% for
regional nerve analgesia vs 17.9% for GA/spinal blocks (p 
0.867). Age did not affect mortality outcome in either groups
of anesthesia modality. Table 1 illustrates the mortality break-
downs mortality for AKA and BKA.
Conclusions: Our analysis did not reveal any mortality
benefit of utilizing regional nerve block over general anes-
thesia or spinal blocks.
Table 1: AKA and BKA mortality
AKA mortality
ALIVE DEATH MORTALITY
AVG AGE
(YRS)
REGIONAL 19 6 24.00% 77.6
GA/SPINAL
(p  0.7945)
46 18 28.10% 77.7
BKA mortality
ALIVE DEATH MORTALITY
AVG AGE
(YRS)
REGIONAL 21 1 4.50% 69.6
GA/SPINAL
(p  0.6563)
42 5 10.60% 72.7
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Objectives: Vascular surgery is accompanied by cardiac
arrhythmias. However, arrhythmias are often short-lived and
asymptomatic,making detection difficult and causing the true
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Volume 51, Number 11S Abstracts 69Sincidence to be understated. In this ongoing study we com-
pared the incidence of arrhythmias using two different moni-
toring devices.
Methods: Patients with sinus rhythm were monitored
with a 72-hour Holter electrocardiography device (Holter-
ECG) (N  350), and combined with a subcutaneously
implanted cardiac loop recorder (Reveal XT®) (N  20),
the latter starting one month prior to surgery, until it was
explanted onemonth post-surgery. New-onset arrhythmias
were noted. Thirty-day postoperative events, defined as
MI, stroke, and cardiac death, were noted.
Results: New-onset perioperative arrhythmias were re-
corded in 45 (13%) and 8 (40%) patients with Holter-ECG
and Reveal respectively. In patients with perioperative ar-
rhythmias, cardiovascular events occurred more frequently
(OR 3.0, 95% CI 1.4-6.4). Using the Reveal device 4
additional patients were identified who experienced periop-
erative cardiovascular events. The incidence of cardiovascu-
lar events with Holter and Reveal monitoring was 11/45
(24%) and 4/8 (50%) respectively.
Conclusions: Vascular surgery patients may develop
paroxysmal arrhythmias outside the recording window of
the 72-hour Holter ECG and are generally asymptomatic.
Continuous implanted cardiac monitors can detect these
paroxysmal episodes of arrhythmias, which in turn could
have important therapeutic consequences.
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Objectives: This study is a multi-center, prospective,
randomized, controlled clinical trial that compared two
methods, the investigational Vascular Sealant and GEL-
FOAM®/Thrombin, for treating anastomotic bleeding.
The objective was to evaluate the safety and effectiveness of
the Vascular Sealant compared with GELFOAM®/
Thrombin when used to seal bleeding anastomotic suture
lines.
Methods: Patients were randomized into the Vascular
Sealant group or the Control GELFOAM®/Thrombin
group. The site (s) were assessed for bleeding immediately
and at intervals of 1, 3, 5, 7.5 and 10 minutes. Subjectswere assessed within 7 days of surgery and at 30 days
post-procedure.
Results: A total of 69 subjects were randomized. The
overall incidence of adverse events, including serious adverse
events, was comparable between the two study groups. Vas-
cular Sealant group sealing success was achieved for 90.7% of
treated subjects [95% CI: 79.7%, 96.9%] and in the Control
group, success was 86.7% [95% CI: 59.5%, 98.3%] (p 
0.072). The secondary endpoint of sealing success at the
anastomosis level was established to be noninferior to the
Control treatment (p  0.048). Immediate Sealing Success
was significantly greater for the Vascular Sealant group com-
pared with the Control group; 51.5% and 10.5%, respectively
(p 0.006).
Conclusions: Due to a small sample size the primary
endpoint did not reach significance. However secondary
endpoints did reach satistical significance and Vascular Seal-
ant appears to be as safe and effective as GELFOAM®/
Thrombin in stopping suture line bleeding. It has an ad-
vantage in achieving immediate hemostasis in over half the
cases. This product may be particularly suited for patients
on antiplatelet and/or anticoagulant agents as well as those
with known hemostatic deficiencies.
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Objectives: Endovascular aneurysm repair (EVAR) is
an established treatment for aortic aneurysm (AAA). Al-
though data is accumulating on radiation risk to patients,
little attention is paid to the radiation doses in individual
steps of EVAR. We aimed to divide an EVAR procedure
into dose related steps to facilitate dose optimization.
Methods: Dose area product (DAP), digital acquisi-
tion (DSA) and fluoroscopy times (FT) for 96 procedures
were analysed from our prospective EVAR database. Effec-
tive dose was calculated using this and computed tomog-
raphy (CT) dose data. Analysis of 7 procedures was used to
break the EVAR into a series of component steps according
to the radiation exposures. Phantom studies determined
the typical entrance surface dose for each procedure step for
the range of exposure parameters selected for the EVAR
procedures, including table height, position and field of
view (FOV).
